Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
NEWTON, Mass., March 07, 2016 -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report fourth quarter and full year 2015 financial results and provide a company update on Monday, March 14, 2016. Karyopharm’s management team will host a conference call and audio webcast at 8:30 a.m. ET on Monday, March 14, 2016 to discuss the financial results and recent business developments.
To access the conference call, please dial (855) 437-4406 (local) or (484) 756-4292 (international) at least five minutes prior to the start time and refer to conference ID 59463471. A live audio webcast of the call will be available under "Events & Presentations" in the Investor section of the Company's website, investors.karyopharm.com/events.cfm. An archived webcast will be available on the Company's website approximately two hours after the event.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE™ compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). In addition to single-agent and combination activity against a variety of human cancers, SINE™ compounds have also shown biological activity in models of inflammation, autoimmune disease, neurological disorders, certain viruses and wound-healing. Karyopharm was founded by Dr. Sharon Shacham and is located in Newton, Massachusetts. For more information, please visit www.karyopharm.com.
Contact: Justin Renz (617) 658-0574 [email protected] Gina Nugent (617) 460-3579 [email protected]
